Trends in anti-osteoporotic medication utilization following fragility fracture in the USA from 2011 to 2019
Authors' conclusion
Besides the overall low utilization rate of osteoporosis treatment in patients following fragility fractures, there has been no change in the treatment utilization rate within the past decade.
Study context
- Population
- Patients older than 65 with fragility fractures sustained from 2011 to 2019, PearlDiver Patient Records Database
- Exposure
- Hip fractures vs Upper extremity fractures vs vertebral compression fractures (VCF)
- Outcome
- Osteoporosis treatment rate: prescription of any of the fourteen most used anti-osteoporotic medications
- Follow-up
- Within 1 year of fragility fracture
Methodological detailsclaims database (PearlDiver Patient Records Database)
- Claims database (PearlDiver Patient Records Database)
Main finding
As reported in the abstract
Osteoporosis treatment rate within 1 year of fragility fracture
- Overall osteoporosis treatment rate
- 8.01%
- Change in overall treatment rate, 2011 to 2018: no change
- P = 0.32
- Trend in treatment rate for VCFs: increased (only fracture category to increase)
- P = 0.048
Observational data: associations, not effects.
Further findings
Trend in treatment rate in VCF, by subgroup
- Increased among patients 65-74 years old
- P < 0.05
- Increased among male patients
- P = 0.013
Trend in treatment rate in upper extremity fractures, patients 70-74 years old
- Increased
- P = 0.038
Trends by medication class
- Bisphosphonate utilization increased
- P = 0.049
- Denosumab utilization increased
- P < 0.001
- Calcitonin utilization decreased
- P < 0.001
- Bisphosphonates the most frequently prescribed class
Original publication
Trends in anti-osteoporotic medication utilization following fragility fracture in the USA from 2011 to 2019. Osteoporos Int. Published 3 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →